About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

As Investment Shrinks Research Slows Down on Mental Health Drugs

by Rukmani Krishna on November 27, 2013 at 11:59 PM
Font : A-A+

As Investment Shrinks Research Slows Down on Mental Health Drugs

Psychiatrists say that research into medications to treat mental health disorders, which affect almost a quarter of the US population, has slowed as major pharmaceutical companies cut back investment in this area.

"The companies seem to have concluded that developing new psychiatric drugs is too risky and too expensive," said Richard Friedman, professor of clinical psychiatry at Weill Cornell Medical College in New York.

Advertisement

The pullback came after a series of failures in clinical trials that evaluated anti-depressants and anti-psychotic medications, he said.

In one recent case, a new treatment for schizophrenia from US drugmaker Eli Lilly (Ly2140023) was scrapped after it failed in a phase 3 clinical trial, leaving the company with a huge loss on the millions it had already invested.
Advertisement

It's been nearly a decade since the last big blockbuster drug -- Eli Lilly's anti-depressant Cymbalta, in 2004 -- hit the market, and that was more than a decade after the previous big seller, Wyeth's anti-depressant Effexor, according to Dr. Friedman.

Friedman said the decline in spending was apparent at the 2011 conference of the American Society for Clinical Pharmacology and Therapeutics, where just 13 of the 300 presentations were related to pharmaceutical interventions and none involved a new psychiatric drug.

"There is very little in the pipeline," said Friedman. "Eventually you have to rely on what is available and what is available is essentially what we call 'me-too drugs.'

"They basically share the same mode of action as the older drugs," he said, noting that some go back as far as the 1950s, albeit the newer ones may be more effective and have fewer side effects.

According to Steven Paul, professor of psychiatry at Weill Cornell Medical College, , the drop in research and development investment has been "very significant."

"It has to be at least half of what has been invested 10 to 15 years ago," Paul, who has previously held senior research positions at Eli Lilly and the National Institutes of Health, told AFP.

Unique challenges in treating the brain

Laboratories often prefer to invest in cancer, heart disease and diabetes, for which biological targets are well-defined and easier to study, Friedman said.

Given that it takes about a billion dollars to develop a new drug, he added, many companies view that as a "huge gamble."

Treating the brain brings unique challenges, said Paul Summergrad, chairman of the department of psychiatry and medicine at Tufts University school of medicine in Boston.

"The brain is extremely complicated to work on," he told AFP.

Psychiatric illness "is generally more likely to be a disorder of both neurochemistry and circuits, as well as complicated gene and environmental interactions," he said.

"It is harder from a scientific standpoint to study these disorders."

Summergrad said new techniques in neuroscience have emerged in recent decades that allow for a better genetic understanding of psychiatric disease, accompanied by new imaging advances that show a range of abnormalities in the brain.

But despite these strides, these techniques remain "relatively new... so I think it's a challenge for the pharmaceutical industry. That why they have in part backed away from the work of taking care of those illnesses."

AFP asked five major pharmaceutical companies for comment on this story, including Merck, Pfizer, Bristol-Myers Squibb, Sanofi and GlaxoSmithKline.

Only Merck responded.

"As we are doing very little in this area, we respectfully decline to participate. Merck is now focusing on Alzheimer's Disease," said Caroline Lappetito, a spokeswoman for Merck.

Thomas Insel, the director of the National Institute of Mental Health, has blogged about the dearth of progress in mental health innovation.

"Paradoxically, while companies are making business decisions to shift away from central nervous system targets, the scientific opportunities for progress have never been better," he wrote in 2010.

He also expressed dismay that his institute's annual budget at $1.4 billion was not enough to pick up the slack from drug firms.

For Liza Gold, a professor of clinical psychiatry at Georgetown University, the lack of new medication is a big problem.

"It's a very difficult thing to say somebody, 'We don't have anything else, this is what we got,'" she told AFP.

Experts still have hope, however, based on a project launched this year by president Barack Obama to unravel the mysteries of the brain, which Friedman said "has definitely got huge promise."

The Brain Research Through Advancing Innovative Neurotechnologies program sets aside $100 million in investment in its first year by a host of federal agencies.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
Breast Cancer Awareness Month 2021 - It's time to RISE
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Adolescence Depression Drug Toxicity Anxiety Disorder Reiki-A Holistic Healing Method Flowers And What They Mean To Us Health Insurance - India Ways to Improve your Intelligence Quotient (IQ) Mental Health - Neurosis vs Psychosis Understanding the Role of Love in Mental Health Effect of Romantic Movies on a Child's Mental Health 
Recommended Reading
Anxiety Disorder
Anxiety disorder involves excessive worry about actual circumstances, events or conflicts. Anyone ca...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Effect of Romantic Movies on a Child's Mental Health
Romantic movies can affect a child''s mental health both positively and negatively and therefore, cr...
Flowers And What They Mean To Us
Flowers can be used as infusion for treating digestive disorders or they can be used as poultice for...
Health Insurance - India
Health insurance has emerged as one of the fastest growing segments in the non-life insurance indust...
Mental Health - Neurosis vs Psychosis
Mental well-being is a concern and abnormal coping of emotions can lead to neurosis or psychosis. Me...
Understanding the Role of Love in Mental Health
Love plays a crucial role in our mental health. Love that comes from a friend, a partner, a sibling,...
Ways to Improve your Intelligence Quotient (IQ)
Intelligence quotient (IQ) is a psychological measure of human intelligence. Regular physical and me...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use